Summary Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates
insulin and suppresses glucagon secretion, inhibits gastric emptying, and reduces appetite …

Summary The dipeptidyl peptidase 4 (DPP‐4) inhibitors enhance the body's own ability to
control blood glucose by increasing the active levels of incretin hormones in the body. Their …

BACKGROUND:: Dipeptidyl peptidase-IV (DPP-IV) inhibitorsrepresent a new class of oral
antihyperglycemic agents. Sitagliptin is an orally active and selective DPP-IV inhibitor …

The incretin hormones are intestinal polypeptides that enhance postprandial insulin
secretion. Gastric inhibitory polypeptide (GIP) was initially thought to regulate gastric acid …

Abstract Objective Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide are incretin hormones, secreted in response to meal ingestion. The incretin …

Type 2 diabetes is characterized by hyperglycemia resulting from insulin resistance in the
setting of inadequate β-cell compensation. Currently available therapeutic agents lower …

Monounsaturated fatty acids, such as oleic acid (OA), and certain milk proteins, especially
whey protein (WP), have insulinotropic effects and can reduce postprandial glycemia. This …

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from enteroendocrine L
cells in response to ingested nutrients. The first recognized and most important action of …

Glucagon-like peptide-1 is an insulinotropic hormone with antidiabetic potential due to its
spectrum of effects, which include glucose-dependent stimulation of insulin and inhibition of …

Current therapies for type 2 diabetes are frequently associated with inadequate control of
postprandial hyperglycemia, weight gain, and, in the case of oral agents, loss of efficacy …